An editorial asks medical schools to treat researchers as capital. The NIH postdoc pay line is the test.

A new European Spine Journal editorial landed online on 19 July 2026 with a title that sounds like a slogan. "The researcher is 'not' an afterthought", by Dino Samartzis and co-authors, asks teaching hospitals, medical schools, and funders to stop treating research labor as a salary line and start depreciating it as institutional capital. The move is not rhetorical. The FY2026 NIH postdoctoral stipend scale is the line item that proves whether any institution is serious.

The editorial is the second programmatic signal from the European Spine Journal's new Co-Editor-in-Chief team. Samartzis took the role with the January 2026 "new chapter" editorial co-authored with Reda Cecchinato. Together, the two pieces form a values statement for the journal's tenure: research is the engine that reshapes clinical care, education, and institutional reputation, not a co-equal pillar beside them.

The argument lands because three independent 2026 institutional reports have converged on the same accounting claim. The Association of American Medical Colleges' 2022 economic impact report, released in 2026, puts US medical schools and teaching hospitals at more than $728 billion in GDP contribution and 7.1 million jobs, with research activities alone generating roughly $33 billion. United for Medical Research's 2026 update on NIH's role in the US economy, drawing on FY2025 grant data, found that NIH grants produced $94.15 billion in economic activity and supported 390,863 jobs, returning about $2.57 for every federal dollar. AAMC and UMR are the GDP case; both put the research worker's output in capital terms, not salary terms.

The Wellcome research culture survey, fielded to more than 4,000 researchers, supplies the second half. Eighty-four percent said they were proud to work in research; only 29 percent felt secure pursuing a research career. Seventy-eight percent said competition had created unkind or aggressive conditions; 61 percent had witnessed bullying or harassment; 43 percent had experienced it; 37 percent felt comfortable speaking up. The Orthopaedic Research Society Spine Section's international musculoskeletal researcher survey, led by Martin and colleagues, found 26.7 percent had observed bullying, harassment, or discrimination, 11.2 percent had experienced it, and 32.8 percent felt unable to speak out without repercussions. The two surveys convert the editorial's "asset" language into working conditions, and the working conditions are the maintenance cost of the asset.

The classification matters because of how budgets are written. A salary line gets cut when the fiscal year tightens; a capital line gets depreciated, then replaced, then written down. AAMC's framing already moves in that direction when it isolates research activity as a distinct economic-impact category. UMR's $2.57-to-$1 ratio is the kind of number a CFO uses to defend a capital line, not a hiring decision. Global rankings, on which teaching hospitals depend for reputation and patient flow, weight research output, citations, and collaboration heavily. A researcher who leaves does not only stop producing papers; the institution's rank signal depreciates with them.

The FY2026 NIH NRSA postdoctoral stipend scale is the falsifier. The NRSA scale is the federal pay line for the early-career researchers who do most of the bench work. If the editorial's framing is real, FY2026 stipends should move toward a maintenance-of-capital model: larger jumps at the 0-to-3 and 3-to-5 year marks, not the historically flat step rates that treat postdocs as an inexpensive labor pool. The published scale shows moderate increases only after seven or more years post-PhD, which is closer to a delayed-earnings trajectory than a capital-maintenance budget.

That gap is the live tension. The institutional language has shifted; the federal pay line has not. The editorial is asking the rest of the field to follow the language shift and then make the pay line catch up. Whether any institution, the journal, a funder, or a teaching hospital, makes the first move on the NRSA-equivalent line of its own budget is the next thing worth watching. The European Spine Journal has now said, twice in seven months, which side of the argument it is on.